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Abstract
Background Transcatheter aortic valve implantation
(TAVI) has been developed to minimize operative mor-
bidity and mortality in high-risk symptomatic patients unﬁt
for open surgery. With the proximity of the aortic valve
annulus to the conduction system there is, however, an
unknown risk of conduction disturbances necessitating
monitoring and often cardiac pacing.
Materials and methods We enrolled 50 consecutive
patients from January 2007 to 2008 in our prospective
evaluation of conduction disturbances measured by surface
and intracardiac ECG recordings. Baseline parameters,
procedural characteristics as well as twelve-lead surface
ECG and intracardiac conduction times were revealed pre-
interventionally, after TAVI and at 7-day follow-up.
Results TAVI was performed successfully in all patients.
During 7 days of follow-up the rate for ﬁrst-degree AV
block raised from 14% at baseline to 44% at day 7
(p\0.001), while rates for type II second- and third-
degree were 0 versus 8% (p\0.001) and 0 versus 12%
(p\0.001), respectively. Similarly, the prevalence of new
left bundle branch block (LBBB) rose from 2 to 54%
(p\0.001). Intracardiac measurements revealed a pro-
longation of both AH and HV interval from 123.7 ± 41.6
to 136.6 ± 40.5 ms (p\0.001) and from 54.8 ± 11.7 to
71.4 ± 20.0 ms (p\0.001), respectively. Pacemaker
implantation at a mean follow-up of 4.8 ± 1.2 days was
subsequently performed in 23 patients (46%) due to com-
plete AV block (12%) and type II second-degree AV block
(8%) while another 13 patients (26%) received a pace-
maker for the combination of new LBBB with marked HV
prolongation. The high rate of ﬁrst-degree AV block was
primarily driven by an increase in HV interval.
Conclusion Cardiac conduction disturbances were com-
mon in the early experience with CoreValve implantation
necessitating close surveillance for at least 1 week.
Keywords ConductiondisordersCoreValveAVblock
Pacemaker  Left bundle branch block  His bundle
Introduction
Rising life expectancy results in an increase in degener-
ative and neoplastic diseases. Population-based observa-
tional studies have revealed that 1–2% of patients over
65 years have moderate to severe aortic stenosis [1].
Current guidelines consider aortic valve replacement as a
class I indication for symptomatic patients [2, 3], facing,
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DOI 10.1007/s00392-011-0400-6however, the fact that one-third of patients are considered
to have an unacceptably high risk for open surgery [4].
Current treatment options for those patients include
medical treatment and percutaneous balloon aortic val-
vuloplasty, although neither has been shown to reduce
long-term mortality of medically treated patients with
symptomatic aortic stenosis with a 1- and 5-year survival
of 60 and 32%, respectively, and only minor short-term
beneﬁts were reported after balloon aortic valvuloplasty
[5–7]. Transcatheter aortic valve implantation (TAVI) has
recently been developed to minimize surgical risk in high-
risk patients with severe symptomatic aortic stenosis who
are refused for conventional open aortic valve replace-
ment. With the anatomical proximity of the conduction
system to the aortic annulus there is potential to develop
conduction disorders in up to 6% even after conventional
surgical aortic valve replacement [8, 9]. Initial experience
with TAVI reported complete AV block and pacemaker
requirement in 5.7–42.5% [10–17]. Better prediction of
pacemaker requirement would be of considerable beneﬁt
in patients undergoing TAVI with respect to potential
need and duration of postoperative monitoring. We
examined both incidence and characteristics of conduction
disorders periinterventionally and during in-hospital fol-
low-up period after TAVI measured by surface and
intracardiac ECG recordings.
Methods
Patients
Between January 2007 and 2008, 50 consecutive patients
who underwent TAVI using the third-generation percuta-
neous self-expanding CoreValve prosthesis (Medtronic,
Minneapolis, MN, USA) were identiﬁed for this study. The
criteria for inclusion and exclusion to the TAVI procedure
have been described elsewhere [10, 11]. In brief, patients
were included with echocardiographic measurements
demonstrating severe native valvular aortic stenosis with
an area \1c m
2,o r\0.6 cm
2/m
2 regardless of adjunct
regurgitation; a diameter of the basal oriﬁce of the stenosed
valve between 20 and 27 mm; and a diameter at the sino-
tubular junction B43 mm. Most importantly, all patients
were considered unﬁt for open surgery with a EuroSCORE
C20% [10, 11, 18]. TAVI was suggested in agreement
between a cardiac surgeon and both, a clinical and inter-
ventional cardiologist; patient’s or referring physician’s
preference was not relevant. Pacemaker implantation at
follow-up was considered as indicated in case of complete
AV block, type II second-degree AV block, and in pres-
ence of new LBBB in combination with HV prolongation
to C75 ms.
Procedure
Details of the implantation procedures have been described
elsewhere [10–17]. In brief, all patients were operated in a
hybrid interventional suite under general anesthesia to
assure stable hemodynamics and minimize patient move-
ment during valve implantation. TAVI was performed via
femoral access under ﬂuoroscopic imaging. The aortic
valve was initially dilated using a standard valvuloplasty
balloon with a nominal diameter similar to the aortic valve
and followed by CoreValve insertion [10, 11].
In each patient, prior to TAVI and aside a right ven-
tricular bipolar pacing lead (Pacel
TM, St. Jude Medical, St
Paul, MN, USA), a 6F quadripolar electrode catheter with
ring electrodes (5-mm interpolar distance) (Webster D
TM,
Biosense Webster, Diamond, USA) was introduced and
advanced to the His bundle. A 6F quadripolar electrode
catheter (Soloist
TM
, Medtronic, Minneapolis, MN, USA)
was advanced to the right atrium and another to the right
ventricle to record a bipolar electrogram and for pro-
grammed atrial and ventricular stimulation. The access
sites for all electrophysiologic electrode catheters were the
femoral veins. With such instrumentation the sinus node
recovery time (SNRT), corrected sinus node recovery time
(c-SNRT), antegrade and retrograde effective refractory
period (ERP) of the AV node, as well as intracardiac
conduction times (atrium to His and His to ventricle time;
AH and HV interval) were assessed. The rationale to
measure SNRT was the observations of sinus node arrest in
a single patient receiving a CoreValve prior this study.
Thus, we wanted to avoid overseeing sinus node pathology
in this elderly patient suffering from a high comorbidity
index. All measurements were done on an Axiom Sensis
TM
(Siemens, Erlangen, Germany) electrophysiology work-
station. The AV nodal ERP was measured by introducing a
single extrastimulus (S2) after a drive train of 8 stimuli at a
ﬁxed rate (S1) (600 ms), at which time the S1–S2 interval
is decreased until the S2 impulse does not conduct to the
His bundle. To assess conduction disorders, patients were
attached to uninterrupted ECG monitoring using the Philips
monitoring system (IntelliVue
TM, Best, The Netherlands)
that is installed at our ICU/IMC unit. All patients were
prophylactically given a temporary pacemaker via the
existing femoral venous access; with VVI mode the active
pacing was 60 bpm for at least 24 h.
Statistical methods
All data were processed using the SPSS statistical package
for windows, release 16.0 (Chicago, IL, USA). The
descriptive statistical characteristics for quantitative
parameters are listed as numbers (n), arithmetic mean
(mean), median (med), minimum (min), maximum (max),
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123and relative frequency (%). The Fisher exact test and v
2-
test were used to compare proportions. A normal distri-
bution of differences was conﬁrmed by the Kolmogorov–
Smirnov test; in presence of normally distributed data
paired-sample t testing was used while with non-normal
distribution the Wilcoxon rank test was required. Differ-
ences were considered signiﬁcant at a probability value of
p\0.05.
Results
The analysis included 22 men and 28 women with a mean
age of 81.5 ± 6.8 years. All patients had qualiﬁed for
TAVI according to recent recommendations [10, 11].
Clinical symptoms included dyspnoea (56%), angina
(42%), syncope (22%) as well as heart failure (38%)
(Table 1). The logistic EuroSCORE operative mortality
estimate was 23.0 ± 17.5% while 4 patients (8%) were
classiﬁed inoperable because of porcelain aorta. Echocar-
diographic mean pressure across the aortic valve was
55 ± 15.4 mmHg with an aortic valve area of 0.7
± 0.2 cm
2 measured by planimetry during transesophageal
echocardiography.
TAVI required a mean procedural and ﬂuoroscopy time
of 109.6 ± 36.4 min and 14.1 ± 1.6 min, respectively,
and was successfully performed in all patients followed by
an intensive care and hospital stay of 2.2 ± 2.8 and
13.8 ± 9.3 days. The placement of electrode catheters
throughout the procedure resulted in an additional ﬂuo-
roscopy time of 2.5 min. Six patients suffered from intra-
procedural circulatory depression and required intermittent
intravenous catecholamines; one patient required 1 DC
shock for ventricular ﬁbrillation induced by wire irritation.
Postinterventional aortography revealed a mean aortic
insufﬁciency grade of 1.2 ± 0.58 (Table 2).
Sinus rhythm was documented at baseline in 39 (78%)
and atrial ﬁbrillation in 9 (18%); ﬁve patients (10%) had
previously implanted pacemakers due to bradyarrhythmia
(n = 3; 6%) and sino-atrial block (n = 2; 4%). Seven
patients (14%) had ﬁrst-degree AV block before TAVI,
which increased to 22 (44%) (p\0.001) at 7-day follow-
up. Similarly, newly developed second-degree AV block
(all of them being type II blocks) was present in 4 (8%) at
follow-up (p\0.001). LBBB, present in 1 patient (2%)
prior to TAVI, was documented at the time of post-pro-
cedural electrogram in 20 patients (40%) eventually rising
to 27 (54%) at 7-day follow-up (p\0.001). The two
patients with pre-existing left anterior hemiblock devel-
oped complete left bundle branch block and the two
patients with pre-existing right bundle branch block
emerged with complete AV block after placement of the
CoreValve prosthesis. All four patients received permanent
pacemaker due to either complete AV block or markedly
prolonged HV conduction.
Of the 22 patients suffering from ﬁrst-degree AV block,
intracardiac measurements revealed 18 cases of HV pro-
longation (13 patients with a prolongation to C75 ms and 5
patients with a prolongation up to 75 ms) while 8 had AH
prolongation without progression to complete heart block
and thus not necessitating a permanent pacemaker. Simi-
larly, ﬁve patients with HV prolongation to values lower
than 75 ms (2 patients with additional new LBBB)
received no pacemaker and had no higher degree conduc-
tion abnormality during observation. Baseline AH and HV
intervals increased from 123.7 ± 41.6 and 54.8 ± 11.7 ms
Table 1 Baseline characteristics of the study population (n = 50)
Variable
Clinical parameters
Male, n (%) 22 (44)
Age (years) 81.5 ± 6.8
BMI (kg/m
2) 26.8 ± 3.8
Hypertension, n (%) 46 (92)
Smoker, n (%) 15 (30)
Diabetes mellitus, n (%) 19 (38)
Creatinine (lmol/l) 133.6 ± 114.5
Renal insufﬁciency (creatinine level[1.5 mg/dl),
n (%)
28 (56)
Chronic obstructive pulmonary disease, n (%) 10 (20)
New York Heart Association functional class
(grade)
3.2 ± 0.6
Logistic EuroSCORE (%) 23.0 ± 17.5
Dyspnoea, n (%) 28 (56)
Angina, n (%) 21 (42)
Syncope, n (%) 11 (22)
Pulmonal artery pressure (mmHg) 41.2 ± 18.2
Porcelain aorta, n (%) 4 (8)
Cardiac decompensation, n (%) 19 (38)
Ischemic heart disease, n (%) 38 (76)
Previous coronary artery by pass graft surgery,
n (%)
6 (12)
Peripheral vessel disease, n (%) 6 (12)
Cerebral vascular disease, n (%) 16 (32)
Echocardiographic parameters
Aortic valve area (cm
2) 0.7 ± 0.2
Left ventricular ejection fraction (%) 47.6 ± 11.4
Peak pressure gradient (mmHg) 86.9 ± 25.9
Mean pressure gradient (mmHg) 55.4 ± 15.4
Aortic annulus dimension (mm) 22.8 ± 3.6
Aortic bulbus dimension (mm) 29.6 ± 3.4
Interventricular septal dimension (mm) 14.1 ± 1.6
Aortic regurgitation grade CI, n (%) 19 (38)
Mitral insufﬁciency Cgrade II, n (%) 43 (86)
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123to 136.6 ± 40.5 and 71.4 ± 20.0 ms at 7-day follow-up
without any signiﬁcant change in SNRT, c-SNRT
(Table 3). Any increasing intracardiac conduction time was
irreversible (Figs. 1, 2).
At 7 days, complete heart block with pacing was present
in 6 cases (12%), while another 4 patients (8%) received a
pacemaker for type II second-degree AV block and further
13 patients (26%) for the combination of new LBBB with
an increase in AV conduction time, especially the HV
intervals C75 ms (dual chamber pacing in 15 and single
chamber pacing in 8 patients). All conduction abnormali-
ties in patients receiving a pacemaker were due to delay or
block in infra-His region. Pacemakers were implanted at
4.8 ± 1.2 days of follow-up. None of the ﬁve patients with
previously implanted pacemakers experienced additional
procedure-related pacemaker indication after TAVI.
Discussion
Aortic valve disease has been associated with cardiac
conduction system disease as aortic stenosis and insufﬁ-
ciency have been associated with both prolonged AV
conduction times and higher degrees of AV block [19–21].
Due to the vicinity of aortic valve and AV node as well as
His bundle, AV block is a common complication of con-
ventional surgical aortic valve replacement and has been
described in up to 6% [8, 9]. New LBBB after surgical
valve replacement is even more common and has been
reported in 18% [8, 9]. Furthermore, development of new
LBBB after surgical aortic valve replacement is associated
with higher rates of complete AV block, syncope, and
sudden cardiac arrest at long term [8, 9, 22]. Such con-
duction disturbances are presumed to result from surgical
trauma to the cardiac conduction tissue during debridement
of the calciﬁed annulus [8, 9, 22].
TAVI is a relatively new alternative to conventional
surgical valve replacement in high-risk patients not eligible
for open surgery [10, 11]. There are only few data
regarding the incidence of early conduction disorders after
TAVI. The incidence of permanent pacemaker implanta-
tion after TAVI with the CoreValve system has been
reported in 20–42.5%, and that of a new LBBB in 50–70%
[12–15, 23]. In the study by Marcheix et al. [23] 30% of
patients required pacemaker implantation due to persistent
AV block [23], whereas Zahn et al. [12] reported a per-
manent pacemaker rate of 42.5% in the German Trans-
catheter Aortic Valve Intervention Registry [12]. Different
rates of pacemaker implantation might be due to different
indications for pacing (e.g. complete AV block, new
LBBB, prolonged AV conduction). A comparison of hard
endpoints like high-grade AV block would be more con-
vincing. Other reasons for different pacemaker implanta-
tion rates might be the learning curve with high
implantation techniques resulting in less compromise of the
compact AV node [23–27].
Although several reports describe changes in surface
ECG, our study is the ﬁrst to note intracardiac conduction
abnormalities for better discriminating new ECG changes
on surface ECG. Interestingly, the evolution to complete
AV block and to LBBB took place over an observation
period of 7 days. Similarly, PQ interval and QRS duration,
as well as AH and HV intervals prolonged and resulted in a
rate of permanent pacemakers of 46%. The AH interval is
considerably affected by patient’s autonomic state when
TAVI procedure is performed under general anesthesia.
However, the main changes during TAVI results in HV
conduction. Scheinman et al. [24] have shown that patients
with an HV interval greater than 100 ms are at high risk to
develop complete AV block. Therefore, the possibility of
progression of LBBB to complete AV block should always
be considered [22, 24, 25] and may explain the liberal use
of pacemakers for conduction disorders observed in our
series of TAVI patients. This liberal approach may be
debatable, but in elderly patients with several comorbidi-
ties preventive pacemaker insertion is justiﬁed by guideline
recommendation [25]. Piazza et al. [26, 27] showed that
some of the initial conduction delay after TAVI was par-
tially reversible at 1-month follow-up and presumably
related to inﬂammation and edema around the conduction
Table 2 Intraoperative data
Parameter
Procedural success, n (%) 50 (100)
Conversion to surgical AVR, n (%) 0 (0)
Intraprocedural circulatory depression, n (%) 6 (12)
Catecholamine therapy, n (%) 6 (12)
Resuscitation, n (%) 2 (4)
Deﬁbrillation, n (%) 1 (2)
Vascular access site complication, n (%) 9 (18)
Contrast agent (ml) 117.2 ± 50.2
Procedure time (min) 109.6 ± 36.4
Fluoroscopy time (min) 14.1 ± 1.6
CoreValve size (mm)
26 23 (46)
29 27 (54)
Pre-TAVI valvuloplasty, n (%) 50 (100)
Post-TAVI valvuloplasty, n (%) 21 (42)
Number of inﬂations after TAVI (n) 1.1 ± 0.2
Balloon diameter (mm) 21.7 ± 2.1
Balloon length (mm) 53.8 ± 12.6
Angiographic aortic insufﬁciency (grade) 1.2 ± 0.58
ICU stay (days) 2.2 ± 2.8
Hospital stay (days) 13.8 ± 9.3
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123pathways [26, 27]; in our series we could not identify a
single case of conduction recovery.
Notably, we demonstrated a higher pacemaker require-
ment rate than seen after open surgical technique. A critical
issue, however, is that, with surgical replacement, the
native valve is explanted, whereas with TAVI, the native
aortic valve remains in situ and is compressed by stent
frame against the surrounding structures. Other potential
sources of local damage can include degeneration and
calciﬁcation of the conduction system, the mechanical or
ischemic effects of pre-implantation balloon valvuloplasty,
or the direct contact and trauma by catheters and guide-
wires with components of the conduction system; however,
trauma from percutaneous balloon aortic valvuloplasty is
often reversible. The close anatomic vicinity of the His
bundle to the non-coronary and right-coronary cusp results
in a mechanical damage of the compact AV node and
bundle of His, predominantly (but not exclusively) of the
Table 3 Electrocardiographic characteristics during follow-up
Variable Before TAVI After TAVI 7 days after
TAVI
p Value before
TAVI versus after
TAVI
p Value after TAVI
versus 7 days after
TAVI
p Value before TAVI
versus 7 days after
TAVI
Rhythm
Sinus, n (%) 39 (78) 39 (78) 38 (76) 0.999 0.873 0.766
Atrial
ﬁbrillation, n (%)
9 (18) 9 (18) 9 (18) 0.999 0.999 0.999
Pacemaker, n (%) 2 (4) 2 (4) 3 (6) 0.999 0.647 0.835
Heart rate
(beats/min)
69.8 ± 11.4 69.6 ± 13.4 66.1 ± 16.2 0.835 0.694 0.372
Surface ECG
PQ interval
(ms)
179.4 ± 48.5 203.5 ± 51.2 210.6 ± 49.5 0.001 0.001 0.03
QRS width
(ms)
98.8 ± 16.8 125.6 ± 29.4 142.0 ± 36.0 0.001 0.001 0.001
QT interval
(ms)
395.0 ± 31.0 410.0 ± 31.5 407.5 ± 27.9 0.714 0.682 0.477
Hemiblock, n (%)
Anterior 4 (8) 1 (2) 2 (4) 0.009 0.055 0.012
Posterior 0 (0) 0 (0) 1 (2) 0.999 0.456 0.348
Bundle branch block, n (%)
Left 1 (2) 20 (40) 27 (54) 0.004 0.001 0.001
Right
a 2 (4) 0 (0) 0 (0) 0.006 0.999 0.001
Atrioventricular block, n (%)
First degree 7 (14) 11 (22) 22 (44) 0.001 0.384 0.001
Second degree
b 0 (0) 4 (8) 4 (8) 0.001 0.994 0.001
Complete 0 (0) 4 (8) 6 (12) 0.001 0.001 0.001
Intracardiac measurement
c-SNRT
(ms)
484.4 ± 68.1 492.8 ± 73.5 478.1 ± 56.7 0.280 0.638 0.612
SNRT
(ms)
1070.5 ± 171.0 1078.7 ± 165.4 1103.9 ± 160.9 0.736 0.882 0.824
AH interval
(ms)
123.7 ± 41.6 129.7 ± 38.8 136.6 ± 40.5 0.263 0.459 0.001
HV interval
(ms)
54.8 ± 11.7 66.8 ± 16.9 71.4 ± 20.0 0.001 0.003 0.001
Antegrade
AVN ERP
408.8 ± 45.1 446.7 ± 91.8 451.4 ± 55.6 0.001 0.638 0.001
Retrograde
AVN ERP
439.3 ± 47.1 464.3 ± 56.4 479.4 ± 66.1 0.046 0.378 0.033
a Both patients suffered from complete AV block during follow-up
b All second-degree AV blocks were type II blocks
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123infra-His region during TAVI. Additionally, compression
from nitinol expansion (over hours and days) explains
further mechanical trauma and ‘‘late’’ onset of conduction
disturbances. Actually we have no data according to the
time course of prosthesis expansion. Our experience
showed that most of the conduction disturbances emerged
within the ﬁrst 7 days.
Nevertheless, with the balloon-expandable shorter
Edwards SAPIEN prosthesis, which is placed in the aortic
annulus without direct impact on left ventricular outﬂow
tract (LVOT), the incidence of AV conduction block
requiring pacemaker was reported between 0 and 6% and
new onset LBBB of 3.3% [28, 29].
Although yet to be investigated, technical strategies to
diminish trauma to the conduction system by TAVI using
the CoreValve revalving system may reduce the risk of
conduction abnormalities. Such strategies may include
limiting the depth of the valve within the LVOT and
keeping the number of pre- and post-valve implantation
balloon valvuloplasties to a minimum. Additionally, oper-
ators should deploy the device only a few millimeters
below the annulus and avoid impacting the septum. A
Fig. 1 Intracardiac
measurements during follow-up
Fig. 2 Electrocardiographic
characteristics during follow-up
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123modiﬁed implantation technique, however, may also
require technical modiﬁcations to avoid malalignment of
valve. Such new challenging technical approach was,
however, not utilized in our early implantation experience.
Conclusion
Cardiac conduction disturbances were common after TAVI
andneedclosesurveillanceatleastduringtheﬁrstweekafter
implantation. The indication for pacemakers in our patient
populationwasliberalandsomewhatprophylacticduetothe
combination of new LBBB with an increase in AV conduc-
tion time, especially HV interval. Further evaluation with
long-term follow-up is required to analyze a potential tem-
poral evolution of these conduction disturbances as well as
progression of the combination of new LBBB with an
increase of AV conduction time to complete heart block.
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